Ciprofloxacin indications

List of indications
Adult patients Pediatric patients (1 to 17 years of age) Adult and pediatric patients
 * Urinary tract infections
 * Acute uncomplicated cystitis in females
 * Chronic bacterial prostatitis
 * Lower respiratory tract infections
 * Acute sinusitis
 * Skin and skin structure infections
 * Bone and joint infections
 * Complicated intra-abdominal infections
 * Infectious diarrhea
 * Typhoid fever (Enteric fever)
 * Uncomplicated cervical and urethral gonorrhea

Urinary tract infections
Urinary Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter diversus, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus epidermidis, Staphylococcus saprophyticus, or Enterococcus faecalis. Return to top

Acute uncomplicated cystitis in females
Acute Uncomplicated Cystitis in females caused by Escherichia coli or Staphylococcus saprophyticus. Return to top

Chronic bacterial prostatitis
Chronic Bacterial Prostatitis caused by Escherichia coli or Proteus mirabilis. Return to top

Lower respiratory tract infections
Lower Respiratory Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, or penicillin-susceptible Streptococcus pneumoniae. Also, Moraxella catarrhalis for the treatment of acute exacerbations of chronic bronchitis. Although effective in clinical trials, Ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae. Return to top

Acute sinusitis
Acute Sinusitis caused by Haemophilus influenzae, penicillin-susceptible Streptococcus pneumoniae, or Moraxella catarrhalis. Return to top

Skin and skin structure infections
Skin and Skin Structure Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus aureus methicillin-susceptible Staphylococcus epidermidis, or Streptococcus pyogenes. Return to top

Bone and joint infections
Bone and Joint Infections caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginosa. Return to top

Complicated intra-abdominal infections
Complicated Intra-Abdominal Infections (used in combination with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis. Return to top

Infectious diarrhea
Infectious Diarrhea caused by Escherichia coli (enterotoxigenic strains), Campylobacter jejuni, Shigella boydii,Shigella dysenteriae, Shigella flexneri or Shigella sonnei when antibacterial therapy is indicated. Return to top

Typhoid fever (Enteric fever)
Typhoid Fever (Enteric Fever) caused by Salmonella typhi. The efficacy of Ciprofloxacin in the eradication of the chronic typhoid carrier state has not been demonstrated. Return to top

Uncomplicated cervical and urethral gonorrhea
Uncomplicated cervical and urethral gonorrhea due to Neisseria gonorrhoeae. Return to top

Pediatric patients (1 to 17 years of age)
Complicated Urinary Tract Infections and Pyelonephritis due to Escherichia coli. Although effective in clinical trials, Ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues. Ciprofloxacin, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals. Return to top

Adult and pediatric patients
Inhalational anthrax (post-exposure): To reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. Return to top